After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...